Pharma News

On July 12, 2022, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Zhongmei Huadong"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd.

• Liraglutide injection
• Obesity

On July 27, AbbVie announced that it had submitted to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for upadacitinib (trade name Rinvoq, 45mg [induction dose] and 15mg and 30 mg [maintenance dose])

• Upadacitinib
• AbbVie
• Crohn
• FDA

Progesterone, a steroid hormone synthesized by the placenta, ovaries and adrenal glands, is essential for reproductive function and regulation of the menstrual cycle

• Progesterone
• Pharma

Sulfonamide products are affected by the breeding market, and the overall price has fallen

• Sulfonamides
• veterinary drug
• vitamin

Ceftiofur sodium, ceftiofur hydrochloride, cephalosporins fell as a whole, the average market transaction price, ceftiofur sodium 1860, down 18.1% year-on-year; ceftiofur hydrochloride 1380, down 20.0% year-on-year

• Cephalosporins
• Penicillins

AbbVie has decided to terminate a collaboration focused on the development of Alzheimer's disease treatment AL003, Alector disclosed in a filing with the U.S. Securities and Exchange Commission a few days ago.

• AbbVie
• Alzheimer
• Immunotherapy
• Alector

The latest weekly influenza report of the National Influenza Center on June 17 (6.6-6.12) showed that the proportion of influenza-like cases (ILI%) among outpatient cases reported by sentinel hospitals in southern provinces was 5.8%

• Oseltamivir
• Anti-influenza drug

As a well-known hypoglycemic drug, metformin plays an important role in the field of diabetes treatment. It is the widest and largest variety in the field of diabetes in terms of its scope of use and scale.

• hypoglycemic drug
• Metformin

Recently, AstraZeneca (AstraZeneca) and Merck & Co. (MSD) jointly announced the results of the Phase 3 PROpel clinical trial of its PARP inhibitor olaparib (Lynparza), published in NEJM Evidence

• AstraZeneca
• Merck
• clinical trial
• Olaparib

On June 21, AstraZeneca announced that the Phase III NEURO-TTRansform study of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) met co-primary endpoints at the interim analysis and secondary endpoint.

• AstraZeneca
• therapy

Ibuprofen is an arylpropionic acid anti-inflammatory, analgesic, analgesic, and anti-rheumatic drug with significant anti-inflammatory, analgesic, and antipyretic effects and less adverse reactions. one of the over-the-counter drugs.

• Ibuprofen
• export volume
• API

Merck is evaluating the possibility of acquiring Seagen, according to the Wall Street Journal. As soon as the news came out, Seagen rose nearly 18% after triggering a circuit breaker.

• Merck
• ADC
• Seagen

According to the British "Times" report, there are rumors that AstraZeneca is considering the acquisition of its London-based partner Mereo BioPharma.

• AstraZeneca
• Mereo
• BioPharma

On June 15, Hansoh Pharma announced that its overseas partner, EQRx, has submitted a New Drug Application (MAA) for the third-generation EGFR inhibitor Almetinib to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and has been accepted as

• Ametinib
• third-generation EGFR inhibitor
• Hansoh pharm

On June 14, EQRx, Inc announced that the UK Medicines and Health Products Regulatory Agency (MHRA) has accepted a Marketing Authorization Application (MAA)

• UK MHRA
• Almetinib

On June 14, CDE's official website showed that AstraZeneca's clinical trial application for AZD8205 was approved for the treatment of advanced or metastatic solid malignancies.

• AstraZeneca
• AZD8205
• clinical trial

On June 14, ‍Bristol-Myers Squibb announced that the world's first and currently only red blood cell maturation agent, Liblose®

• red blood cell
• Maturation agent

On June 13, the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China stated that AstraZeneca submitted a marketing application for a new drug of category 5.1

• AstraZeneca
• Mersk
• Inhibitor

On May 13, 2022, the U.S. Food and Drug Administration approved Eli Lilly and Company's Mounjaro™ (tirzepatide) injection

• Eli Lily
• Tirzepatide
• Dual agonist

On June 9, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China announced that Tonghua Dongbao Pharmaceutical has submitted a marketing application for GLP-1 analog liraglutide injection

• Liraglutide
• injection